





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:	A1	(11) International Publication Number: WO 00/505			
C12N 15/12, C07K 14/47, G01N 33/566, A61K 38/17, C07K 16/28, A61K 39/395, C12N 15/62		(43) International Publication Date:	31 August 2000 (31,08.00)		
(21) International Application Number: PCT/US (22) International Filing Date: 18 February 2000 (CY, DE, DK, ES, FI, FR, GB,			
(30) Priority Data:		Published			

US

US

(71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).

22 February 1999 (22.02.99)

8 October 1999 (08.10.99)

(72) Inventors; and

60/121,170

60/158,566

- (75) Inventors/Applicants (for US only): CHIARI, Rita, [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE). COULIE. Pierre [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE). BOON-FALLEUR, Thierry [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE).
- (74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of

(54) Title: TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES

Stimulator	AT	IF produ	ced_by	clone 19	(pg/ml)
cells	O	20		60	80

(57) Abstract

The invention describes HLA class II binding peptides encoded by the EphA3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the EphA3 gene.